Lisa Bodei
Memorial Sloan Kettering Cancer Center
Internal medicineRadiologyPathologyOncologyProgressive diseaseNeuroendocrine tumorsDiseaseLiquid biopsyProstate cancerNuclear medicineRadionuclide therapyPeptide receptorIn patientCancer researchMedicineBiomarker (medicine)Chromogranin ASomatostatin receptorGastroenterology
126Publications
25H-index
1,370Citations
Publications 126
Newest
#1Valentina Ambrosini (UNIBO: University of Bologna)H-Index: 42
#2Jolanta Kunikowska (Medical University of Warsaw)H-Index: 17
Last. James C. Yao (University of Texas MD Anderson Cancer Center)H-Index: 74
view all 31 authors...
Abstract Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a...
10 CitationsSource
#1Erik Mittra (OHSU: Oregon Health & Science University)H-Index: 5
#2Amanda Abbott (Society of Nuclear Medicine and Molecular Imaging)
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 3 authors...
1 CitationsSource
#1Kelley Lauren Coffman (MSK: Memorial Sloan Kettering Cancer Center)
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Nitya Raj (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
view all 14 authors...
368Background: 177Lu-DOTATATE is an approved therapy for somatostatin receptor (sstr) positive gastroenteropancreatic neuroendocrine tumors (NETs). There are little data available on response and o...
1 CitationsSource
#1Elisabeth O’Dwyer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Michael J. Morris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 66
view all 3 authors...
Theranostics in men with metastatic castration-resistant prostate cancer (mCRPC) has been developed to target bone and the tumor itself. Currently, bone-directed targeted alpha therapy with radium-223 (223Ra) is the only theranostic agent proven to prolong survival in men with mCRPC who have symptomatic bone metastases and no known visceral metastases. The clinical utility and therapeutic success of 223Ra has encouraged the development of other tumor-targeting theranostic agents in mCRPC, primar...
3 CitationsSource
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
In contemplating peer-reviewed information and the business of science divulgation, in which we all are immersed, one may wonder what legacy a very quoted article will hand down to posterity and what core of knowledge will stand the tests of time, of fashion, and of planned obsolescence of
Source
#1Andrew L. Lin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
#2Mark T.A. Donoghue (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Eliza B. Geer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
view all 7 authors...
A small subset of pituitary adenomas grow despite maximal treatment with standard therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate two patterns of growth: they may be locally aggressive or metastasize distantly, either hematogenously or through the spinal fluid. Further surgery and radiotherapy may be helpful for palliation of symptoms, but they are rarely definitive in the management of these malignant tumors. The only chemotherapy with established activity in th...
4 CitationsSource
#1Wolfgang A. Weber (TUM: Technische Universität München)H-Index: 67
#2Johannes Czernin (UCLA: University of California, Los Angeles)H-Index: 94
Last. H. William Strauss (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 22
view all 20 authors...
### Wolfgang A. Weber and Johannes Czernin Scientific discoveries published in The Journal of Nuclear Medicine over the past 60 years have shaped the practice of medicine and form the foundation for the future of nuclear medicine, molecular imaging, and theranostics. Nuclear medicine now provides
7 CitationsSource
#1George Sgouros (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 2
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Jessie R. Nedrow (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 8
view all 4 authors...
3 CitationsSource
#1George Sgouros (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 2
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Jessie R. Nedrow (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 8
view all 4 authors...
Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach to treating many types of cancer. In RPT, radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate by physiological mechanisms. Almost all radionuclides used in RPT emit photons that can be imaged, enabling non-invasive visualization of the biodistribution of the therapeutic agent. Compared with almost all other systemic cancer treatmen...
65 CitationsSource
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Heiko Schöder (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 77
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 8 authors...
Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide receptors and is typically used for neuroendocrine tumours (NETs). Some of the key challenges in its use are the prediction of efficacy and toxicity, patient selection, and response optimisation. In this Review, we assess current knowledge on the molecular profile of NETs and the strategies and tools used to predict, monitor, and assess the toxicity of PRRT. The few mutations in tumour genes that can be e...
17 CitationsSource